Evidence for the Conservation of Conformational Topography at Five Major GABAA/Benzodiazepine Receptor Subsites. Potent Affinities of the (S)-Enantiomers of Framework-Constrained 4,5-Substituted Pyrroloimidazobenzodiazepines

Medicinal Chemistry Research

Volumn 7, Issue 1, 1997, Pages 25-35

  Liu, Ruiyan ^a   Zhang, Puwen ^a   Gan, Tong ^a   McKernan, Ruth M ^b   Cook, James M ^a  

^a UNIVERSITY OF WISCONSIN MILWAUKEE   (United States)

^b NEUROSCIENCE RESEARCH CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0002926929     PISSN: 10542523     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Martin, M.J., Trudell, M.L., Diaz-Arauzo, H., Allen, M.S., Deng, L., Schultz, C.A., Tan, Y.-C., Bi, Y., Narayanan, K., Dorn, L.J., Koehler, K.F., Skolnick, P. and Cook, J.M. J. Med. Chem., 1992, 35, 4105-4117.
2. Sieghart, W. Pharm. Rev., 1995, 47, 181-234.
3. Verdoorn, T., Draguhn, A., Ymer, S., Seeburg, P.H. and Sakmann, B. Neuron, 1990, 4, 919-928.
4. Sigel, E., Baur, R., Trube, G., Möhler, H. and Malherbe, P. Neuron, 1990, 5, 703-711.
5. Benavides, J., Peny, B., Ruano, D., Vitorica, J. and Scatton, B. Brain Res., 1993, 604, 240-250.
6. Mertens, S., Benke, D. and Mohler, H. J. Biol. Chem., 1993, 268, 5965-5973.
7. Sieghart, W., Eichinger, A., Richards, J.G. and Mohler, H. J. Neurochem., 1987, 48, 46-52.
8. Wisden, W., Herb, A., Wieland, H., Keinanen, K., Luddens, H. and Seeburg, P.H. FEBS Lett., 1991, 289, 227-230.
9. Gunnersen, G., Kaufman, C. and Skolnick, P. Neuropharmacology, in press,
10. Gu, Z.Q., Wong, G., Dominguez, C., de-Costa, B.R., Rice, K.C. and Skolnick, P. J. Med. Chem., 1993, 36, 1001-1006.
11. Fryer, R.I., Zhang, P., Lin, K.-Y., Upasani, R.B., Wong, G. and Skolnick, P. Med. Chem. Res., 1993, 3, 183-191.
12. Wong, G., Koehler, K.F., Skolnick, P., Gu, Z.Q., Ananthan, S., Schönholzer, P., Hunkeler, W., Zhang, W. and Cook, J.M. J. Med. Chem., 1993, 36, 1820-1830.
13. Wong, G., Gu, A.-Q., Fryer, R.I. and Skolnick, P. Med. Chem. Res., 1992, 2, 217-224.
14. Wong, G. and Skolnick, P. Eur. J. Pharmacol. Mol. Pharm. Sec., 1992, 225, 63-68.
15. Zhang, P., Zhang, W., Liu, R., Harris, B., Skolnick, P. and Cook, J.M. J. Med. Chem., 1995, 38, 1679-1688.
16. Wisden, W., Laurie, D.J., Monyer, H. and Seeburg, P.H. J. Neurosci., 1992, 12, 1040-1062.
17. McKernan, R.M., Quirk, K., Prince, R., Cox, P.A., Gillard, N.P., Ragan, C.I. and Whiting, P.J. Neuron, 1991, 7, 667-676.
18. Whiting, J.G., Mckernan, R.M. and Iversen, L.L. Proc. Natl. Acad. Sci. USA, 1990, 87, 9966-9970.
19. A-Receptor subtypes differing in α-subunit composition display unique pharmacological properties In GABAergic Synoptic Transmission; Biggio, G., Concas, A. and Costa, E., Ed.; Raven Press: New York; 1992, pp 41-53.
20. Hadingham, K.L., Wingrove, P., Le-Bourdelles, B., Palmer, K.J., Ragan, C.I. and Whiting, P.J. Mol. Pharmacol., 1993, 43, 970-975.
21. Doble, A. and Martin, I.L. Trends Pharmacol. Sci., 1992, 13, 76-81.
22. Liu, R., Hu, R.J., Zhang, P., Skolnick, P. and Cook, J.M. J. Med. Chem., 1996, 39, 1928-1934.
23. Haefely, W., Kyburz, E., Gerecke, M. and Mohler, H. Recent advances in the molecular pharmacology of benzodiazepine receptors and in the structure-activity relationships of their agonists and antagonists. In Adv. Drug Res.; Testa, B., Ed.; Academic Press: New York; 1985, Vol. 14; pp 165-322.
24. Liu, R., Zhang, P., McKernan, R.M., Wafford, K. and Cook, J.M. Med. Chem. Res., 1995, 5., 700-709.
25. Zhang, W., Koehler, K.F., Zhang, P. and Cook, J.M. Drug Design and Discovery, 1995, 12, 193-248.
26. Fryer, R.I., Gu, Z.Q. and Wang, C.G. J. Heterocycl. Chem., 1991, 28, 1661-1669.
27. Watjen, F., Baker, R., Engelstoff, M., Herbert, R., MacLeod, A., Knight, A., Merchant, F., Moseley, J., Saunders, J., Swain, C.J., Wong, E. and P., S.J. J. Med. Chem., 1989, 32, 2282-2291.
28. Liu, R., Gillard, N.P., Gu, Z.-Q., Rice, K., McKernan, R. and Cook, J.M. Search for α5 benzodiazepine receptor subtype specific ligands based on the structure of sarmazenil (Ro15-4513),presented at the 56th Annual Scientific Meeting of the College on the Problem of Drug Dependence, the Breakers, West Palm Beach, June 18-23 (1994), Oral Communications VI.
29. Wafford, K.A., Whiting, P.J. and Kemp, J.A. Mol. Pharmacol., 1993, 43, 240-244.
30. Wafford, K.A., Bain, C.J., Whiting, P.J. and Kemp, J.A. Mol. Pharmacol, 1993, 44, 437-442.
31. Hadingham, K.L., Wingrove, P.B., Wafford, K.A., Bain, C., Kemp, J.A., Palmer, K.J., Wilson, A.W., Wilcox, A.S., Sikela, J.M., Ragan, C.I. and Whiting, P.J. Mol. Pharm., 1993, 44, 1211-1218.
32. Satisfactory analytical data were obtained on the target compounds depicted in Tables 1 and 2. CHN.
33. Compound 4a: mp 248-249°C; 4b: mp 248-249°C; 5a: mp 93-94°C; 5b: mp 93-94 °C; 6a: mp 163-164°C; 6b: mp 163-164°C; 7a: mp 126-127°C; 7b: mp 126-127°C; 7c: mp 187-188°C; 7d: mp 154-156°C; 11: mp 193-194; 12: mp 195-196°C; 13: mp 182-183°C; 14a: mp 217-218°C; 14b: mp 227-228°C; 14c: mp 216-217°C. All compounds were recrystallized from EtOAc.